8-K: Clene's CNM-Au8 Shows Significant ALS Biomarker Reductions

Clene Inc. announced statistically significant reductions in key ALS biomarkers, NfL and GFAP, for its drug CNM-Au8, supporting an accelerated approval pathway.

Summary

• Statistically significant reductions in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) were observed in ALS participants treated with CNM-Au8.
• Biomarker improvements are strongly associated with longer survival, demonstrating an 80% reduction in the risk of death for participants with the greatest declines in NfL and GFAP.
• These analyses followed FDA recommendations to strengthen the persuasiveness of original NfL findings and build on prior constructive FDA interactions.
• Clene has requested a Type C meeting with the FDA in the first quarter of 2026 to present the full dataset and plans an NDA submission under the accelerated approval pathway in the same quarter.
• The Phase 3 RESTORE-ALS trial is planned to serve as the post-approval confirmatory study.
• CNM-Au8 demonstrated a strong safety profile across over 1,000 patient years of exposure, with no serious adverse events identified as related to treatment.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial results, meeting FDA recommendations for biomarkers and showing significant survival benefits in ALS patients. The planned accelerated approval pathway and strong safety profile are very favorable, indicating substantial progress and potential for market entry.

Positives

• Statistically significant reductions in NfL levels were observed in the NIH-EAP (p = 0.0373) and confirmed in the HEALEY ALS Platform Trial (p=0.0013).
• Statistically significant declines in GFAP were identified during the double-blind period in the HEALEY ALS Platform Trial (p<0.05) and were highly correlated with NfL change.
• NfL and GFAP biomarker declines are strongly associated with improved survival, showing an 80% reduction in the risk of death (Cox HR: 0.191, 95% CI: 0.047 – 0.782, p=0.0210) for participants with the greatest declines.
• Updated survival analyses demonstrated clinically meaningful and statistically significant survival benefit for CNM-Au8 30 mg, with a 73% reduction in risk of death in the full analysis set (p=0.0144) and a 77% reduction in the comparable risk set (p=0.0151) at one year.
• Placebo-to-CNM-Au8 switchers showed a significant restricted mean survival time (RMST) benefit of +30.7 days at one year following treatment initiation (95% CI 7.52 – 53.85, p=0.0094).
• The data is remarkably consistent across multiple analyses, including the NIH-EAP, HEALEY OLE, and placebo switchers, reinforcing the drug's potential disease-modifying activity.
• CNM-Au8 maintains a strong safety profile across over 1,000 patient years of exposure, with no significant safety concerns or serious adverse events identified as related to treatment.

Negatives

• In the primary analysis population of non-bulbar onset participants, the Week 36 AUC NfL change was not statistically significant (p=0.2085).

Risks

• General market conditions may impact company performance.
• Clinical trials may not demonstrate the efficacy and safety of drug candidates to the satisfaction of regulatory authorities, or may not produce positive results, potentially leading to additional costs or delays.
• Clinical results for drug candidates may not support further development or marketing approval.
• Actions of regulatory agencies may affect the initiation, timing, and progress of clinical trials and marketing approval.
• The company's ability to achieve commercial success for its drug candidates, if approved, is not guaranteed.
• The company has a limited operating history and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates is a risk.

Future Outlook

Clene plans to hold a Type C meeting with the FDA in the first quarter of 2026 to present the full dataset supporting accelerated approval. The company intends to submit an NDA under the accelerated approval pathway in the same quarter, with the Phase 3 RESTORE-ALS trial serving as the post-approval confirmatory study.

Management Comments

• "We followed the FDAs roadmap and the data delivered. Statistically significant NfL reductions in more advanced real-world ALS patients; a second independent disease-specific biomarker (GFAP) that moves in lock-step with NfL and is itself statistically significant; and clear evidence in placebo switchers (placebo-to-CNM-Au8) showing that CNM-Au8-treated participants biomarkers follow nearly identical trajectories seen in the original active arm during the double-blind treatment phase of the HEALEY ALS Platform Trial. This is a remarkably consistent dataset that makes a strong case for accelerated approval. We look forward to presenting these analyses to the Division in the requested Type C meeting in the first quarter of 2026 and working with the FDA toward an NDA submission for accelerated approval." Rob Etherington, President and CEO of Clene.
• "We believe these data show the potential enduring effect of CNM-Au8, because this NIH-EAP data includes participants who are generally more advanced than a typical ALS clinical trial population and still show concordant NfL decline. The consistency of NfL and GFAP reductions in more advanced patients treated in the Expanded Access Program is particularly compelling and suggests potential disease-modifying activity of CNM-Au8." Dr. Jinsy Andrews, MD, MSc, Director of the Amyotrophic Lateral Sclerosis Center and Medical Director of Clinical Trials in the Department of Neurology at NYU Grossman School of Medicine and principal investigator of the NIH-sponsored EAP.

Industry Context

The positive biomarker and survival data for CNM-Au8, particularly in a challenging and rapidly progressive disease like ALS, positions Clene as a significant innovator in neurodegenerative disease treatment. The drug's mechanism, focusing on mitochondrial health and the NAD pathway, offers a novel therapeutic approach that could address underlying disease mechanisms more effectively than current standard-of-care treatments. Successful accelerated approval would provide a much-needed new option for ALS patients and validate this therapeutic strategy, potentially influencing future research and development in the broader neurodegenerative field.

Comparison to Industry Standards

• The effect size for NfL decline in the NIH-EAP (Week 36 AUC GMR of 0.914) was similar to that observed in the original double-blind phase of the HEALEY ALS Platform Trial (Week 24 AUC GMR of 0.901).
• Survival benefit was demonstrated against 'concurrent Regimen A controls' in the HEALEY ALS Platform Trial, showing a 73-77% reduction in the risk of death.
• Comparisons of NIH-EAP participants to 'natural history ALS controls' were made using the U.S. ANSWER ALS dataset, which was selected for its reliability and defensibility for regulatory purposes over a previously considered European dataset.
• The NIH-EAP data includes participants who are generally more advanced than a typical ALS clinical trial population, yet still showed concordant NfL decline, suggesting robust efficacy even in a more challenging patient group.

Stakeholder Impact

• Shareholders: Highly positive news, likely to lead to increased share price due to significant clinical progress and a clear path to accelerated FDA approval for a major neurodegenerative disease.
• Patients (ALS): Offers significant hope for a new, potentially disease-modifying treatment with a strong safety profile, addressing a high unmet medical need.
• Medical Community: Provides compelling evidence for a novel therapeutic approach in ALS, potentially influencing treatment paradigms and clinical practice.
• Regulatory Authorities: The company is actively engaging with the FDA, following their recommendations, which could streamline the approval process and facilitate access to a new treatment.

Next Steps

• Clene will host an investor webcast on December 3, 2025, at 8:30 am ET to provide an update on its CNM-Au8 program in ALS.
• The company has requested a Type C meeting with the FDA and anticipates it will occur during the first quarter of 2026 to present the full dataset.
• Clene plans to submit an NDA under the accelerated approval pathway in the first quarter of 2026.
• The planned Phase 3 RESTORE-ALS trial will serve as the post-approval confirmatory study.

Key Dates

Recommendation

The filing details statistically significant and clinically meaningful biomarker reductions (NfL, GFAP) and a substantial survival benefit (73-80% reduction in risk of death) for CNM-Au8 in ALS patients. These robust results were achieved following FDA recommendations and strongly support an accelerated approval pathway, with an NDA submission planned for Q1 2026. The drug also exhibits a strong safety profile across extensive patient exposure. Given the high unmet medical need in ALS and the compelling positive data, this represents a significant de-risking event and a strong catalyst for future growth, making it a compelling 'strong buy' for investors.

Keywords

ALS, Amyotrophic Lateral Sclerosis, CNM-Au8, Clene, Neurodegenerative Disease, Biomarker, NfL, GFAP, FDA Accelerated Approval, NDA Submission, Clinical Trial, Survival Benefit, Neuroprotection, Mitochondrial Health, Biopharmaceutical